A Study to Determine the Safety and Tolerability of Escalating Doses of INS365 Ophthalmic Solution
Phase 2
Completed
- Conditions
- Dry Eye Disease
- Registration Number
- NCT00680108
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Brief Summary
The purpose of this study is to evaluate the safety and tolerability of INS365 Ophthalmic Solution when applied topically as eyedrops in patients with mild to moderate dry eye disease.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Not specified
- Target Recruitment
- 62
Inclusion Criteria
- Best corrected visual acuity 20/40 in each eye
- 2 out 5 specified symptoms
- Corneal fluorescein staining score greater than or equal to 3 out of 15
Read More
Exclusion Criteria
- Unable to stop concomitant medications
- Have had intraocular surgery in previous 90 days
- Have excluded systemic or ocular disease
- Wear contact lenses and are not willing to remove them
- Have intraocular pressure greater than 22 mg Hg
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Visual acuity Evaluation of adverse events Ocular symptomatology Biomicroscopy Ophthalmoscopy
- Secondary Outcome Measures
Name Time Method Unanesthetized Schirmer test